Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Colorcon
Healthtrust
Citi
Medtronic
Mallinckrodt
McKesson
Moodys

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,629,179

« Back to Dashboard

Which drugs does patent 8,629,179 protect, and when does it expire?

Patent 8,629,179 protects CONCERTA and is included in one NDA.

Protection for CONCERTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-eight patent family members in seventeen countries.
Summary for Patent: 8,629,179
Title:Methods and devices for providing prolonged drug therapy
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Gupta; Suneel K. (Sunnyvale, CA), Guinta; Diane R. (Palo Alto, CA), Christopher; Carol A. (Belmont, CA), Saks; Samuel R. (Burlingame, CA), Hamel; Lawrence G. (Mountain View, CA)
Assignee: Alza Corporation (Palo Alto, CA)
Application Number:12/581,699
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,629,179
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,629,179

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-001 Aug 1, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-004 Apr 1, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-002 Aug 1, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-003 Dec 8, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,629,179

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,521,067 Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms ➤ Sign Up
6,548,610 Method and apparatus for reducing static charges during polymerization of olefin polymers ➤ Sign Up
2,015,125,493 ➤ Sign Up
6,930,129 Methods and devices for providing prolonged drug therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
Harvard Business School
Healthtrust
Colorcon
Chubb
McKesson
Deloitte
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.